HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

ASH 2022: Multiple myeloma roundup

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Cancer survivors' stories: An African perspective